Researchers at National Taiwan University have uncovered how a protein called CASK acts as a hidden accelerator for non-small cell lung cancer, opening a potential new avenue for treatment. In work published in the Journal of Biomedical Science, the team discovered that when CASK is silenced—essentially turned off—it triggers a cascade that slows cancer growth by awakening p21, a crucial tumor-suppressing gene that acts as the body's natural brake on runaway cells.
Non-small cell lung cancer, which accounts for the majority of lung cancer cases, has long been a difficult target for treatment. Understanding the molecular switches that fuel its growth is essential to developing better therapies. The National Taiwan University findings suggest that CASK has been quietly helping cancer cells thrive by blocking p21, and that removing this obstacle could shift the balance back toward the patient.
When the researchers depleted CASK in cancer cells, something striking happened: p21 expression surged dramatically, both in normal growth conditions and in nutrient-starved environments. The increase came not from changes in how stable the p21 protein was, but from a boost in how often the p21 gene was being transcribed—essentially the cancer cells were forced to make more of this protective protein. When the team administered UC2288, a drug that blocks p21, the growth suppression vanished, proving that p21 was central to the effect.
The mechanism turns out to be elegantly orchestrated. CASK normally helps cancer cells maintain high levels of EGFR, a growth-promoting receptor on the cell surface. It does this by slowing the trafficking of EGFR proteins toward destruction in late endosomes—essentially keeping the accelerator pressed down. When CASK disappears, EGFR levels drop, and with them, the activation of two downstream signaling pathways called ERK and AKT. This quieting of the growth signal allows p21 to rise unchecked, bringing the cell cycle to a halt.
Notably, this p21 boost happens independently of p53, the famous tumor suppressor gene. While p53 normally contributes to baseline p21 levels, the dramatic increase seen after CASK silencing occurs through a different route entirely—one that doesn't depend on p53 being present or functional. This is significant because many cancers have already disabled p53, meaning this CASK-targeting approach could still work even in those difficult cases.
The researchers also discovered that CASK regulates what's known as the EGFR autocrine loop, a self-reinforcing system where cells produce their own growth signals. Silencing CASK increased expression of TGF-α, a major ligand that binds to and activates EGFR. This finding suggests the protein controls growth through multiple, interconnected pathways.
"These findings suggest that CASK acts as a positive regulator of NSCLC growth by modulating EGFR trafficking, AKT/ERK signaling, and p21 expression," explains Prof. Wan-Wan Lin from the Department of Pharmacology at National Taiwan University.
The work opens a tantalizing possibility: targeting CASK could potentially stop lung cancer by simultaneously hitting multiple growth pathways at once. For patients facing this aggressive disease, the discovery represents a new target worth pursuing in the long journey toward more effective treatments.